Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical is viewed as a high-quality leader in a large, underpenetrated robotic surgery market, with more than 11,000 da Vinci systems placed worldwide, over 6,600 in the US, and more than 16 million da Vinci procedures performed globally. Its appeal is reinforced by best-in-class execution, including Q2'26 revenue of $2.89B, EPS of $2.80, gross margin of 70.0%, and operating margin of about 42%, alongside 468 system placements and a 12% increase in installed base. The company’s moat is further strengthened by recurring instruments-and-accessories revenue, a 70% lease mix that buffers hospital budget pressure, and innovation such as dV5, XiR, and the planned extended use program, which should expand adoption and support durable top- and bottom-line growth.

Intuitive Surgical is facing a deteriorating fundamental setup as its long-standing valuation premium has been compressed by intensified competition, capital budget pressure, and only limited procedure growth, while hospital spending constraints may slow installed-base expansion. U.S. procedure growth moderated to 12% y/y in Q2'26 from 14% in Q1'26, with elective deferrals, GLP-1 headwinds in bariatrics, and the law of large numbers signaling a less robust demand environment even as management sees some temporary effects. Although FY26 revenue is modeled at $11.719B and adj. EPS at $10.73, the company also faces China pricing pressure, slower trade-in cycles, and rising operating complexity that could pressure margins and earnings durability.